ASCENDIS PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 140.9 USD | -0.90% |
|
-6.72% | +11.86% |
| Sales 2024 * | 425M 452M | Sales 2025 * | 742M 790M | Capitalization | 7.55B 8.04B |
|---|---|---|---|---|---|
| Net income 2024 * | -236M -251M | Net income 2025 * | 10M 10.64M | EV / Sales 2024 * | 18.7 x |
| Net Debt 2024 * | 390M 415M | Net Debt 2025 * | 323M 343M | EV / Sales 2025 * | 10.6 x |
| P/E ratio 2024 * |
-30.8
x | P/E ratio 2025 * |
3,158
x | Employees | 879 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 10.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ascendis Pharma A/S
More recommendations
| 1 day | -0.90% | ||
| 1 week | -6.72% | ||
| Current month | -6.80% | ||
| 1 month | -4.20% | ||
| 3 months | +5.95% | ||
| 6 months | +54.69% | ||
| Current year | +11.86% |
1 week
140.23
150.19
1 month
140.23156.84
Current year
119.03161.00
1 year
66.03161.00
3 years
61.58178.71
5 years
61.58183.98
10 years
11.92183.98
| Managers | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Scott Smith
DFI | Director of Finance/CFO | 50 | 16-08-07 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Albert Cha
CHM | Chairman | 51 | 14-10-31 |
| General Counsel | 53 | 07-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.48% | 0 M€ | 0.00% | - | |
| 0.45% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 140.9 | -0.90% | 222,169 |
| 24-04-17 | 142.2 | +0.47% | 299,396 |
| 24-04-16 | 141.5 | -2.57% | 367,491 |
| 24-04-15 | 145.2 | -0.55% | 379,111 |
| 24-04-12 | 146 | -3.31% | 318,762 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
132.1
EUR
Average target price
166.7
EUR
Spread / Average Target
+26.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.86% | 8.05B | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.78% | 21.66B | |
| -18.35% | 20.77B | |
| -8.28% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- ASND Stock
